OBJECTIVE: Patients with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy lack neuronal nitric oxide synthase (nNOS). nNOS mediates physiological sympatholysis, thus ensuring adequate blood supply to working muscle. In mice lacking dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardiac muscle performance. Sildenafil also improves blood flow in patients with BMD. We therefore hypothesized that sildenafil would improve blood flow, maximal work capacity, and heart function in patients with BMD. METHODS: A randomized, double-blind, placebo-controlled crossover design with two 4-week periods of treatment, separated by 2-week washout was used. We assessed brachial artery blood flow during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality; cardiac function was evaluated by magnetic resonance imaging (MRI) at rest and during maximal handgrip exercise. Muscle nNOS and PDE5 were tested with Western blotting in 5 patients. RESULTS:Sixteen patients completed all skeletal muscle evaluations, and 13 completed the cardiac MRI investigations. Sildenafil had no effect on any of the outcome parameters. No serious adverse effects were recorded. PDE5 and nNOS were deficient in 5 of 5 biopsies. INTERPRETATION: Despite positive evidence from animal models of dystrophinopathy and physiological findings in patients with BMD, this double-blind, placebo-controlled clinical study showed no effect of sildenafil on blood flow, maximal work capacity, and heart function in adults with BMD. This discrepancy may be explained by a significant downregulation of PDE5 in muscle.
RCT Entities:
OBJECTIVE:Patients with Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy lack neuronal nitric oxide synthase (nNOS). nNOS mediates physiological sympatholysis, thus ensuring adequate blood supply to working muscle. In mice lacking dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardiac muscle performance. Sildenafil also improves blood flow in patients with BMD. We therefore hypothesized that sildenafil would improve blood flow, maximal work capacity, and heart function in patients with BMD. METHODS: A randomized, double-blind, placebo-controlled crossover design with two 4-week periods of treatment, separated by 2-week washout was used. We assessed brachial artery blood flow during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality; cardiac function was evaluated by magnetic resonance imaging (MRI) at rest and during maximal handgrip exercise. Muscle nNOS and PDE5 were tested with Western blotting in 5 patients. RESULTS: Sixteen patients completed all skeletal muscle evaluations, and 13 completed the cardiac MRI investigations. Sildenafil had no effect on any of the outcome parameters. No serious adverse effects were recorded. PDE5 and nNOS were deficient in 5 of 5 biopsies. INTERPRETATION: Despite positive evidence from animal models of dystrophinopathy and physiological findings in patients with BMD, this double-blind, placebo-controlled clinical study showed no effect of sildenafil on blood flow, maximal work capacity, and heart function in adults with BMD. This discrepancy may be explained by a significant downregulation of PDE5 in muscle.
Authors: Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham Journal: Circulation Date: 2015-05-05 Impact factor: 29.690
Authors: Jeovanna Lowe; Kyle T Floyd; Neha Rastogi; Eric J Schultz; Jessica A Chadwick; Sarah A Swager; Jonathan G Zins; Feni K Kadakia; Suzanne Smart; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Subha V Raman; Paul M L Janssen; Jill A Rafael-Fortney Journal: J Neuromuscul Dis Date: 2016
Authors: Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar Journal: Mol Ther Date: 2014-10-17 Impact factor: 11.454
Authors: Muhammad Z Afzal; Melanie Reiter; Courtney Gastonguay; Jered V McGivern; Xuan Guan; Zhi-Dong Ge; David L Mack; Martin K Childers; Allison D Ebert; Jennifer L Strande Journal: J Cardiovasc Pharmacol Ther Date: 2016-03-02 Impact factor: 2.457
Authors: Giulio Cossu; Stefano C Previtali; Sara Napolitano; Maria Pia Cicalese; Francesco Saverio Tedesco; Francesca Nicastro; Maddalena Noviello; Urmas Roostalu; Maria Grazia Natali Sora; Marina Scarlato; Maurizio De Pellegrin; Claudia Godi; Serena Giuliani; Francesca Ciotti; Rossana Tonlorenzi; Isabella Lorenzetti; Cristina Rivellini; Sara Benedetti; Roberto Gatti; Sarah Marktel; Benedetta Mazzi; Andrea Tettamanti; Martina Ragazzi; Maria Adele Imro; Giuseppina Marano; Alessandro Ambrosi; Rossana Fiori; Maria Pia Sormani; Chiara Bonini; Massimo Venturini; Letterio S Politi; Yvan Torrente; Fabio Ciceri Journal: EMBO Mol Med Date: 2015-12 Impact factor: 12.137
Authors: Rachel T Sullivan; Ngoc T Lam; Margaret Haberman; Margaret J Beatka; Muhammad Z Afzal; Michael W Lawlor; Jennifer L Strande Journal: BMC Cardiovasc Disord Date: 2021-06-15 Impact factor: 2.298